Æterna Zentaris has posted a net income of $12.03m, or $0.19 per diluted share, compared to net loss of $14.49m, or $0.27 per diluted share, for the prior year period.
The significant increase in net earnings is largely attributable to the significant increase in license fee revenues, combined with lower comparative R&D expenses, partly offset by increased SG&A expenses and depreciation and amortization charges.
For the full year ended December 31, 2009, Æterna Zentaris has posted a net loss of $24.72m, or $0.43 per diluted share, compared to $59.81m, or $1.12 per diluted share, for the year ago period.
Revenues were $63.23m for the 12 months, compared to $38.47m for the year ago period.
Juergen Engel, president and CEO of Æterna Zentaris, said: “Over the course of this year, we look forward to further progress in North America with Keryx’s Phase 3 trial with perifosine in multiple myeloma, as well as their initiation of a Phase 3 trial with this same compound in colon cancer.
“Overall in 2010, our focus will be on continuing the development of our innovative late-stage compounds and on garnering interest from potential partners for the benefit of both patients and shareholders.”